Entera Bio Ltd.

EnteraBio Ltd. is a biopharmaceutical company focused on developing oral peptide therapies to treat critical health issues such as osteoporosis and obesity, leveraging innovative delivery systems to enhance therapeutic outcomes. Founded in 2010, EnteraBio Ltd. is based in Jerusalem, Israel, and specializes in the development of oral delivery systems for peptide pharmaceuticals.

The company has executed three deals, with its most recent deal occurring on June 28, 2018, when it completed an IPO raising USD 11. 00 mn. The current CEO is Miranda Toledano. Entera Bio develops oral peptide therapeutics, particularly targeting osteoporosis and obesity.

Its N-Tab™ platform stabilizes peptides in the gastrointestinal tract, enhancing absorption. The flagship product, EB613, is a once-daily oral treatment for postmenopausal women with osteoporosis, while the company is also advancing an oral formulation of oxyntomodulin and an oral GLP-2 peptide tablet for patients with rare malabsorption conditions. These products are aimed primarily at North American and European markets. Entera Bio generates revenue from its therapeutic product offerings through partnerships and collaborations with healthcare providers, pharmacies, and hospitals.

The company utilizes a business-to-business model, particularly for EB613 and other peptide formulations, through agreements and possible licensing with pharmaceutical partners. Pricing structures reflect the therapeutic value, although specific prices are undisclosed. EnteraBio plans to utilize the proceeds from its IPO on June 28, 2018, amounting to USD 11. 00 mn, to advance its product pipeline and expand market reach.

The company is developing additional oral peptide therapies and aims to target expansion into new regions beyond North America and Europe in the coming years. Upcoming product launches are being designed to bolster the company's portfolio in the growing market for oral therapies.